Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage.

Dahia PL.

J Clin Endocrinol Metab. 2013 Jul;98(7):2679-81. doi: 10.1210/jc.2013-2191. No abstract available.

PMID:
23837189
2.

Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.

Crona J, Delgado Verdugo A, Maharjan R, Stålberg P, Granberg D, Hellman P, Björklund P.

J Clin Endocrinol Metab. 2013 Jul;98(7):E1266-71. doi: 10.1210/jc.2012-4257. Epub 2013 May 2.

PMID:
23640968
3.

Multiple pheochromocytomas and paragangliomas in a young patient carrying a SDHD gene mutation.

Novosel A, Heger A, Lohse P, Schmidt H.

Eur J Pediatr. 2004 Dec;163(12):701-3.

PMID:
15365827
4.

Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.

Kytölä S, Nord B, Elder EE, Carling T, Kjellman M, Cedermark B, Juhlin C, Höög A, Isola J, Larsson C.

Genes Chromosomes Cancer. 2002 Jul;34(3):325-32.

PMID:
12007193
5.

Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C; European-American Paraganglioma Study Group.

JAMA. 2004 Aug 25;292(8):943-51. Erratum in: JAMA. 2004 Oct 13;292(14):1686.

PMID:
15328326
6.

Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas.

Geli J, Nord B, Frisk T, Edström Elder E, Ekström TJ, Carling T, Bäckdahl M, Larsson C.

Int J Oncol. 2005 May;26(5):1385-91.

PMID:
15809732
7.

Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology.

Edström E, Mahlamäki E, Nord B, Kjellman M, Karhu R, Höög A, Goncharov N, Teh BT, Bäckdahl M, Larsson C.

Am J Pathol. 2000 Feb;156(2):651-9.

8.

Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.

Nölting S, Grossman AB.

Endocr Pathol. 2012 Mar;23(1):21-33. doi: 10.1007/s12022-012-9199-6. Review.

PMID:
22391976
9.

Familial pheochromocytomas and paragangliomas.

King KS, Pacak K.

Mol Cell Endocrinol. 2014 Apr 5;386(1-2):92-100. doi: 10.1016/j.mce.2013.07.032. Epub 2013 Aug 7. Review.

10.

Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications.

Barletta JA, Hornick JL.

Adv Anat Pathol. 2012 Jul;19(4):193-203. doi: 10.1097/PAP.0b013e31825c6bc6. Review.

PMID:
22692282
11.

Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.

Korpershoek E, Petri BJ, van Nederveen FH, Dinjens WN, Verhofstad AA, de Herder WW, Schmid S, Perren A, Komminoth P, de Krijger RR.

Endocr Relat Cancer. 2007 Jun;14(2):453-62.

12.

Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.

Geli J, Kiss N, Karimi M, Lee JJ, Bäckdahl M, Ekström TJ, Larsson C.

Clin Cancer Res. 2008 May 1;14(9):2551-9. doi: 10.1158/1078-0432.CCR-07-1867.

13.

In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.

Toledo RA, Qin Y, Srikantan S, Morales NP, Li Q, Deng Y, Kim SW, Pereira MA, Toledo SP, Su X, Aguiar RC, Dahia PL.

Endocr Relat Cancer. 2013 May 21;20(3):349-59. doi: 10.1530/ERC-13-0101. Print 2013 Jun.

14.

No child left behind in SDHB testing for paragangliomas and pheochromocytomas.

Schiffman JD.

J Clin Oncol. 2011 Nov 1;29(31):4070-2. doi: 10.1200/JCO.2011.37.8695. Epub 2011 Oct 3. No abstract available.

15.

Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Dannenberg H, Komminoth P, Dinjens WN, Speel EJ, de Krijger RR.

Endocr Pathol. 2003 Winter;14(4):329-50. Review.

PMID:
14739490
16.

Pheochromocytoma/Paraganglioma: Review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma.

Fishbein L, Orlowski R, Cohen D.

J Clin Hypertens (Greenwich). 2013 Jun;15(6):428-34. doi: 10.1111/jch.12084. Epub 2013 Mar 15. Review.

17.

Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.

Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacchè M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL.

JAMA. 2010 Dec 15;304(23):2611-9. doi: 10.1001/jama.2010.1830.

PMID:
21156949
18.

Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.

Nakamura E, Kaelin WG Jr.

Endocr Pathol. 2006 Summer;17(2):97-106. Review.

PMID:
17159241
19.

Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma.

Welander J, Andreasson A, Juhlin CC, Wiseman RW, Bäckdahl M, Höög A, Larsson C, Gimm O, Söderkvist P.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1352-60. doi: 10.1210/jc.2013-4375. Epub 2014 Apr 2.

PMID:
24694336
20.

[Pheochromocytomas and paragangliomas: implications of new insights for diagnosis and treatment].

van der Kleij-Corssmit EP, Havekes B, Vriends AH, Jansen JC, Romijn JA.

Ned Tijdschr Geneeskd. 2008 Mar 1;152(9):489-93. Review. Dutch.

PMID:
18389879
Items per page

Supplemental Content

Write to the Help Desk